Effects of Inhaled Corticosteroids on the Innate Immunological Response to Pseudomonas aeruginosa Infection in Patients with COPD

Inhaled corticosteroids (ICS) use is associated with an increased risk of Pseudomonas aeruginosa (PA) infection in patients with COPD. We aimed to evaluate the effects of ICS on alveolar macrophages in response to PA in COPD patients with and without baseline ICS treatment (COPD and COPD + ICS, resp...

Descripción completa

Detalles Bibliográficos
Autores: Cerón-Pisa, Noemi, Shafiek, Hanaa, Martín-Medina, Aina, Verdú, Javier, Jordana-Lluch, Elena, Escobar-Salom, Maria, Bover Barceló, Isabel, López-Causapé, Carla, Oliver, Antonio, Juan, Carlos, Iglesias, Amanda, García-Cosío, Borja
Tipo de recurso: artículo
Fecha de publicación:2022
País:España
Institución:Instituto de Salud Carlos III (ISCIII)
Repositorio:Repisalud
Idioma:inglés
OAI Identifier:oai:repisalud.isciii.es:20.500.12105/23424
Acceso en línea:https://hdl.handle.net/20.500.12105/23424
Access Level:acceso abierto
Palabra clave:Enfermedad Pulmonar Obstructiva Crónica
Receptor Toll-Like 2
Humanos
Budesonida
Infecciones por Pseudomonas
Corticoesteroides
Administración por Inhalación
Budesonide
Administration, Inhalation
Adrenal Cortex Hormones
Toll-Like Receptor 2
Pulmonary Disease, Chronic Obstructive
Humans
Pseudomonas Infections
Descripción
Sumario:Inhaled corticosteroids (ICS) use is associated with an increased risk of Pseudomonas aeruginosa (PA) infection in patients with COPD. We aimed to evaluate the effects of ICS on alveolar macrophages in response to PA in COPD patients with and without baseline ICS treatment (COPD and COPD + ICS, respectively) as well as smoker and nonsmoker controls. To do so, cells were infected with PA and cotreated with budesonide (BUD) or fluticasone propionate (FLU). The analysis of NF-?B and c-jun activity revealed a significant increase in both factors in response to PA cotreated with BUD/FLU in smokers but not in COPD or COPD + ICS patients when compared with PA infection alone. The expression of Toll-like receptor 2 (TLR2) and the transcription factor c-jun were induced upon PA infection in nonsmokers only. Moreover, in the smoker and COPD groups, there was a significant increase in TLR2 and a decrease in c-jun expression when treated with BUD/FLU after PA infection, which were not observed in COPD + ICS patients. Therefore, the chronic use of ICS seemingly makes the macrophages tolerant to BUD/FLU stimulation compared with those from patients not treated with ICS, promoting an impaired recognition of PA and activity of alveolar macrophages in terms of altered expression of TLR2 and cytokine production, which could explain the increased risk of PA infection in COPD patients under ICS treatment.